How many drugs treat Acute bacterial bronchitis?

Drug Landscape tracks 10 marketed treatments for Acute bacterial bronchitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-bacterial-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute bacterial bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute bacterial bronchitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute bacterial bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Acute bacterial bronchitis
Lg Chem Ltd · 2 drugs in Acute bacterial bronchitis
Bayer AG · 1 drug in Acute bacterial bronchitis
Burke Therap · 1 drug in Acute bacterial bronchitis
Generic (originally Abbott/AbbVie) · 1 drug in Acute bacterial bronchitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Acute bacterial bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Acute bacterial bronchitis
Otsuka · 1 drug in Acute bacterial bronchitis
Pfizer · 1 drug in Acute bacterial bronchitis
Pfizer Inc. · 1 drug in Acute bacterial bronchitis
Poitiers University Hospital · 1 drug in Acute bacterial bronchitis
Teva Pharmaceuticals USA · 1 drug in Acute bacterial bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute bacterial bronchitis:

Cite this brief

Drug Landscape (2026). Acute bacterial bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-bacterial-bronchitis. Accessed 2026-06-10.

Acute bacterial bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing